{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004939","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.047501+00:00","generated_at":"2026-05-28T02:47:31.206339+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Madrigal reports preliminary Rezdiffra Q4 2024 net sales $100M–$103M; over 11,800 patients on therapy","bullets":["Preliminary Q4 2024 Rezdiffra net sales $100M–$103M, full-year $177M–$180M.","Year-end cash, equivalents and marketable securities ~$931M.","Over 11,800 patients on Rezdiffra as of December 31, 2024.","EMA decision on Rezdiffra MAA expected mid-2025; German launch targeted H2 2025.","MAESTRO-NASH OUTCOMES trial in compensated cirrhosis fully enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004939","json":"https://secwatch.observer/filing/0001193125-25-004939.json","markdown":"https://secwatch.observer/filing/0001193125-25-004939.md","text":"https://secwatch.observer/filing/0001193125-25-004939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312525004939/0001193125-25-004939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312525004939/d925380d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:47:31.206339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}